A comparative double-blind controlled for the effect of fenofibrate treatment on the expression of genes of cholesterol homeostasis, inflammation and cell proliferation in carotid plaques asymptomatic arteriosclerosis. [Etude controlee comparative en double aveugle de l'effet d'un traitement par le fenofibrate sur l'expression des genes de l'homeostasie du cholesterol, de l'inflammation et de la proliferation cellulaire dans les plaques arterosclereuses carotidiennes asymptomatiques.]

Trial Profile

A comparative double-blind controlled for the effect of fenofibrate treatment on the expression of genes of cholesterol homeostasis, inflammation and cell proliferation in carotid plaques asymptomatic arteriosclerosis. [Etude controlee comparative en double aveugle de l'effet d'un traitement par le fenofibrate sur l'expression des genes de l'homeostasie du cholesterol, de l'inflammation et de la proliferation cellulaire dans les plaques arterosclereuses carotidiennes asymptomatiques.]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2011

At a glance

  • Drugs Fenofibrate (Primary)
  • Indications Atherosclerosis
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms FENOGEN
  • Most Recent Events

    • 29 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top